Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.

We love to hear from our listeners. Send us a message. (buzzsprout.com/1011661/fan_mail/new)
On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the leadership lessons that come with running a scrappy virtual biotech.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (lifescienceleader.com/solution/the-business-of…) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (www9.lifescienceleader.com/business-of-biotech…).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: linkedin.com/in/bencomer